Company / Working Capital
KalVista Pharmaceuticals, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$196.5M
FY2025
5-year range
$157.3M / $254.5M
FY2021-FY2025
Trend
-3.1%
vs FY2024
Sector context
#173 of 213
Health Care
What the data says
KalVista Pharmaceuticals, Inc.'s working capital of $197M is lower than 81% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 10 years, ranging from $21M in FY2016 to $254M in FY2021.
Based on SEC 10-K filings.
$197M in FY2025 with a 5-year CAGR of +19.4%.
Improved from $157M to $197M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +2.6%
- 5-Year CAGR
- +19.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 213This company $196.5M Sector average $934.6M
▼
-79.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.4%, indicating consistent growth.
- In FY2025, working capital decreased 3.1% year-over-year.
- Ranks #173 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $196.5M | -3.1% |
| FY2024 | $202.9M | +29.0% |
| FY2023 | $157.3M | -13.6% |
| FY2022 | $182.1M | -28.5% |
| FY2021 | $254.5M | +214.3% |
| FY2020 | $81.0M | -16.9% |
| FY2019 | $97.5M | +169.6% |
| FY2018 | $36.2M | +16.0% |
| FY2017 | $31.2M | +45.6% |
| FY2016 | $21.4M | -57.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026